LONDON (Alliance News) - Imperial Innovations Group PLC Friday said the third-largest company in its portfolio is set to publish positive new data after a controlled study.
In a statement, Imperial Innovations said that Veryan Medical will Friday publish the full two-year data from the Mimics randomized controlled study of its BioMimics 3D Stent System at the 15th Annual New Cardiovascular Horizons Conference in New Orleans.
According to Imperial Innovations, the results confirm that BioMimics 3D provides a significant improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention. Patency refers to being open or free of blockage.
Veryan's stents are designed to mimic the vascular system with a three-dimensional helical shape, which helps for a natural, swirling blood flow. The stent is also designed to help certain arteries involved in knee flexion.
Veryan has received CE Mark approval for the BioMimics 3D stent and plans to launch the stent in Europe later this year.
"These are very encouraging data that continue to show the BioMimics 3D stent in a positive light compared to other market-leading stent solutions and suggests a favourable and competitive foundation for commercialisation in the US and Europe," Chief Executive Russ Cummings said in a statement.
"In the light of these results, we will revisit our strategic options for commercialising Veryan's novel 3D helical stents, which could range from completing strategic partnerships around the technology platform to building a further funding round with the aim of taking the product through pre-market approval PMA in the US," Cummings added.
Veryan was formed in 2003 from a technology spin out from Imperial College in London. Its BioMimics 3D technology is based on research by Professor Colin Caro into the link between blood flow mechanics and vascular disease. Imperial Innovations first invested in Veryan in 2003. On January 31, Imperial Innovations had a 44.3% stake in the company.
Imperial Innovations shares were quoted up 1.3% at 395.00 pence Friday.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2014 Alliance News Limited. All Rights Reserved.
